Logotipo do repositório
 

Publicação:
Triiodothyronine and breast cancer

dc.contributor.authorSibio, Maria Teresa de [UNESP]
dc.contributor.authorOliveira, Miriane de [UNESP]
dc.contributor.authorMoretto, Fernanda Cristina Fontes [UNESP]
dc.contributor.authorOlimpio, Regiane Marques Castro [UNESP]
dc.contributor.authorConde, Sandro José [UNESP]
dc.contributor.authorLuvizon, Aline Carbonera [UNESP]
dc.contributor.authorNogueira, Célia Regina [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2015-12-07T15:31:13Z
dc.date.available2015-12-07T15:31:13Z
dc.date.issued2014-08-10
dc.description.abstractThe thyroid hormones (THs), triiodothyronine (T3) and thyroxine (T4), are essential for survival; they are involved in the processes of development, growth, and metabolism. In addition to hyperthyroidism or hypothyroidism, THs are involved in other diseases. The role of THs in the development and differentiation of mammary epithelium is well established; however, their specific role in the pathogenesis of breast cancer (BC) is controversial. Steroid hormones affect many human cancers and the abnormal responsiveness of the mammary epithelial cells to estradiol (E2) in particular is known to be an important cause for the development and progression of BC. The proliferative effect of T3 has been demonstrated in various types of cancer. In BC cell lines, T3 may foster the conditions for tumor proliferation and increase the effect of cell proliferation by E2; thus, T3 may play a role in the development and progression of BC. Studies show that T3 has effects similar to E2 in BC cell lines. Despite controversy regarding the relationship between thyroid disturbances and the incidence of BC, studies show that thyroid status may influence the development of tumor, proliferation and metastasis.en
dc.description.affiliationDepartment of Internal Medicine, Botucatu Medical School, Univ Estadual Paulista-UNESP, Botucatu, SP 18618-970, Brazil.
dc.description.affiliationUnespDepartment of Internal Medicine, Botucatu Medical School, Univ Estadual Paulista-UNESP, Botucatu, SP 18618-970, Brazil.
dc.format.extent503-508
dc.identifierhttp://dx.doi.org/10.5306/wjco.v5.i3.503
dc.identifier.citationWorld Journal Of Clinical Oncology, v. 5, n. 3, p. 503-508, 2014.
dc.identifier.doi10.5306/wjco.v5.i3.503
dc.identifier.issn2218-4333
dc.identifier.pmcPMC4127619
dc.identifier.pubmed25114863
dc.identifier.urihttp://hdl.handle.net/11449/131058
dc.language.isoeng
dc.publisherBaishideng Publishing Group Inc
dc.relation.ispartofWorld Journal Of Clinical Oncology
dc.relation.ispartofsjr1,358
dc.rights.accessRightsAcesso restrito
dc.sourcePubMed
dc.subjectBreast canceren
dc.subjectMammary gland and metabolismen
dc.subjectThyroid hormoneen
dc.subjectTriiodothyronineen
dc.titleTriiodothyronine and breast canceren
dc.typeArtigo
dcterms.rightsHolderBaishideng Publishing Group Inc
dspace.entity.typePublication
unesp.author.lattes7607038776901890[7]
unesp.author.orcid0000-0002-4014-0660[7]
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt
unesp.departmentClínica Médica - FMBpt

Arquivos